1254229-30-5

Basic information

• Product Name: N-{4-[4-chloro-6-({3-[5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl]-1H-pyrazol-4-yl}amino)pyrimidin-2-ylthio]phenyl}cyclopropanecarboxamide
• Synonyms: N-{4-[4-chloro-6-({3-[5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl]-1H-pyrazol-4-yl}amino)pyrimidin-2-ylthio]phenyl}cyclopropanecarboxamide
• CAS NO: 1254229-30-5
• Molecular Weight: 602.119
• Mol File: 1254229-30-5.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-{4-[4-chloro-6-({3-[5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl]-1H-pyrazol-4-yl}amino)pyrimidin-2-ylthio]phenyl}cyclopropanecarboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-{4-[4-chloro-6-({3-[5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl]-1H-pyrazol-4-yl}amino)pyrimidin-2-ylthio]phenyl}cyclopropanecarboxamide(1254229-30-5)
• EPA Substance Registry System: N-{4-[4-chloro-6-({3-[5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl]-1H-pyrazol-4-yl}amino)pyrimidin-2-ylthio]phenyl}cyclopropanecarboxamide(1254229-30-5)

Safety Data

• Hazardous Substances Data: 1254229-30-5(Hazardous Substances Data)

Upstream product

• 825619-03-2 4-(3,4-dinitrobenzyl)-morpholine 
• 528-45-0 3,4-dinitrobenzoic acid 
• 825619-02-1 4-morpholin-4-ylmethylbenzene-1,2-diamine 
• 825619-29-2 4-((2-(4-nitro-1H-pyrazol-3-yl)-1H-benzo[d]imidazole-5-yl)methyl)morpholine 
• 825619-30-5 3-(5-(morpholinylmethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-4-amine 
• 24376-18-9 3,4-dinitrobenzoyl chloride 
• 65003-28-3 (3,4-dinitrophenyl)(morpholin-4-yl)methanone 

Relevant articles and documents

Design, synthesis, quantum chemical studies and biological activity evaluation of pyrazole-benzimidazole derivatives as potent Aurora A/B kinase inhibitors

Novel pyrazole-benzimidazole derivatives have been designed and synthesized. The entire target compounds were determined against cancer cell lines U937, K562, A549, LoVo and HT29 and were screened for Aurora A/B kinase inhibitory activity in vitro. The compounds 7a, 7b, 7i, 7k and 7l demonstrated significant cancer cell lines and Aurora A/B kinase inhibitory activities. Molecular modeling studies suggested the derivatives have bound in the active site of Aurora A kinase through the formation of four hydrogen bonds. Quantum chemical studies were carried out on these compounds to understand the structural features essential for activity. The cellular activity of 7k was also tested by immunofluorescence.